204 related articles for article (PubMed ID: 12079633)
1. Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis.
Spencer JM; Gordon M; Goldberg DJ
J Cosmet Laser Ther; 2002 Mar; 4(1):19-23. PubMed ID: 12079633
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
[TBL] [Abstract][Full Text] [Related]
3. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines.
Carruthers A; Carruthers J; Flynn TC; Leong MS
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S60-8. PubMed ID: 17241416
[TBL] [Abstract][Full Text] [Related]
4. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles.
Sadick NS
Dermatol Surg; 2003 May; 29(5):501-7; discussion 507. PubMed ID: 12752518
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
6. Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin A injection alone: a split-face, rater-blinded, randomized control trial.
Dubina M; Tung R; Bolotin D; Mahoney AM; Tayebi B; Sato M; Mulinari-Brenner F; Jones T; West DP; Poon E; Nodzenski M; Alam M
J Cosmet Dermatol; 2013 Dec; 12(4):261-6. PubMed ID: 24305424
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A.
Alster TS; Lupton JR
Dermatol Surg; 2003 May; 29(5):516-8. PubMed ID: 12752520
[TBL] [Abstract][Full Text] [Related]
8. Eyebrow height after botulinum toxin type A to the glabella.
Carruthers A; Carruthers J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S26-31. PubMed ID: 17241411
[TBL] [Abstract][Full Text] [Related]
9. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin: examining duration of effect in facial aesthetic applications.
Flynn TC
Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study.
Sadick NS; Faacs
Dermatol Surg; 2002 Sep; 28(9):817-21. PubMed ID: 12269875
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
[TBL] [Abstract][Full Text] [Related]
13. An observational study on glabellar wrinkle patterns in Indians.
Kamat A; Quadros T
Indian J Dermatol Venereol Leprol; 2019; 85(2):182-189. PubMed ID: 29620040
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
[TBL] [Abstract][Full Text] [Related]
15. Management of the ageing eyebrow and forehead: an objective dose-response study with botulinum toxin.
Levy JL; Pons F; Jouve E
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):711-6. PubMed ID: 16836501
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion.
Flynn TC; Clark RE
Dermatol Surg; 2003 May; 29(5):519-22; discussion 522. PubMed ID: 12752521
[TBL] [Abstract][Full Text] [Related]
17. Supraciliary wrinkles and botulinum toxin A.
Ghalamkarpour F; Robati RM; Aryanejad F; Toossi P
Clin Exp Dermatol; 2010 Jun; 35(4):388-91. PubMed ID: 19874314
[TBL] [Abstract][Full Text] [Related]
18. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment.
de Almeida AR; da Costa Marques ER; Banegas R; Kadunc BV
Dermatol Surg; 2012 Sep; 38(9):1506-15. PubMed ID: 22804914
[TBL] [Abstract][Full Text] [Related]
19. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
Carruthers A; Carruthers J; Cohen J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422
[TBL] [Abstract][Full Text] [Related]
20. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
Alimohammadi M; Andersson M; Punga AR
Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
